Novartis & W.K. Buckley
This article was originally published in The Tan Sheet
Executive Summary
Novartis is "currently evaluating the opportunity of expanding" Buckley's cough/cold line in U.S. in wake of marketing, distribution deal between the two companies. Toronto-based firm's top-selling Buckley's Mixture cough syrup trades on its "tastes awful and it works" claim and has been sold in U.S. since 1930s; firm launched a $2.1 mil. North American ad campaign three years ago (1"The Tan Sheet" Aug. 16, 1999, p. 5). Buckley's line rounds out Novartis' Canadian cough/cold offerings, which include Triaminic syrups for children, NeoCitran hot liquid powder, Otrivin nasal spray. Companies announced "innovative" agreement Nov. 15 that provides Novartis with "exclusive and indefinite rights to sales, marketing and distribution of Buckley's products throughout the world," according to Novartis...